Results 11 to 20 of about 22,935 (284)

Concurrent Use of Oral Anticoagulants and Sulfonylureas in Individuals With Type 2 Diabetes and Risk of Hypoglycemia: A UK Population-Based Cohort Study [PDF]

Frontiers in Medicine, 2022
ObjectiveTo investigate the association of concurrent use of oral anticoagulants (OACs) and sulfonylureas and the risk of hypoglycemia in individuals with type 2 diabetes mellitus (T2DM).Research Design and MethodsA retrospective cohort study was ...
Hassan Alwafi, Hassan Alwafi, Ian C. K. Wong, Ian C. K. Wong, Ian C. K. Wong, Ian C. K. Wong, Ian C. K. Wong, Abdallah Y. Naser, Amitava Banerjee, Amitava Banerjee, Amitava Banerjee, Pajaree Mongkhon, Pajaree Mongkhon, Cate Whittlesea, Alaa Alsharif, Li Wei, Li Wei, Li Wei   +17 more
doaj   +5 more sources

Pharmacogenomics of Sulfonylureas Response in Relation to rs7754840 Polymorphisms in Cyclin-Dependent Kinase 5 Regulatory Subunit-associated Protein 1-like (CDKAL1) Gene in Iranian Type 2 Diabetes Patients

Advanced Biomedical Research, 2018
Background: Sulfonylureas are important drugs of choice for treatment of type 2 diabetes mellitus (T2DM). It is suggested that differential response to sulfonylureas from T2DM patients is under influence of single nucleotide polymorphisms in some of the ...
Goljahan Soltani, Zahra Hatefi, Ahmad Reza Salehi, Sharifeh Khosravi, Moosa Rahimi Ghiasi, Keimer Teke, Ashraf Aminorroaya, Rasoul Salehi   +7 more
doaj   +2 more sources

Pharmacometabolomics of sulfonylureas in patients with type 2 diabetes: a cross-sectional study [PDF]

Journal of Pharmacy & Pharmaceutical Sciences
BackgroundSulfonylureas have been a longstanding pharmacotherapy in the management of type 2 diabetes, with potential benefits beyond glycemic control.
Khaled Naja, Najeha Anwardeen, Sara S. Bashraheel, Mohamed A. Elrayess, Mohamed A. Elrayess   +4 more
doaj   +2 more sources

Pretreatment of Sulfonylureas Reducing Perihematomal Edema in Diabetic Patients With Basal Ganglia Hemorrhage: A Retrospective Case-Control Study

Frontiers in Neurology, 2021
Background: The sulfonylurea receptor 1–transient receptor potential melastatin 4 (SUR1–TRPM4) channel is a target key mediator of brain edema. Sulfonylureas (SFUs) are blockers of the SUR1–TRPM4 channel.
Zhang Jingjing, Zhao Jingjing, Hui Bo, Wang Le, Wei Jingya, Wei Dong, Yang Fang, Jiang Wen   +7 more
doaj   +1 more source

Adding Sodium–Glucose Co-Transporter 2 Inhibitors to Sulfonylureas and Risk of Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frontiers in Endocrinology, 2021
BackgroundHypoglycemia is an important event that could be related to increased mortality in patients with diabetes. The risk of hypoglycemia is not clearly illustrated to increase when Sodiumglucose co-transporter 2 (SGLT-2) inhibitors are used ...
Meng Jiang, Qiaoshu Liu, Tiejian Jiang, Paul Nizigiyimana, Minxiang Lei   +4 more
doaj   +1 more source

Sulfonylureas or biguanides is associated with a lower risk of rheumatoid arthritis in patients with diabetes: A nationwide cohort study

Frontiers in Medicine, 2022
ObjectiveDiabetes mellitus (DM) is associated with immune dysregulation, while sulfonylureas or biguanides have been linked to anti-inflammatory mechanisms.
Yu-Jih Su, Yu-Jih Su, Jing-Yang Huang, Jing-Yang Huang, Cong-Qiu Chu, James Cheng-Chung Wei, James Cheng-Chung Wei, James Cheng-Chung Wei   +7 more
doaj   +1 more source

Sulfonylureas for Treatment of Periodontitis-Diabetes Comorbidity-Related Complications: Killing Two Birds With One Stone

Frontiers in Pharmacology, 2021
Periodontitis is one of the most prevalent oral inflammatory diseases leading to teeth loss and oral health problems in adults. Periodontitis mainly affects periodontal tissue by affecting the host immune system and bone homeostasis.
Luxi Yang, Qing Ge, Zhitong Ye, Lijing Wang, Lijing Wang, Liping Wang, Mubarak Ahmed Mashrah, Janak L. Pathak   +7 more
doaj   +1 more source

Sulfonylureas Use Is Not Associated With Increased Infarct Size in Patients With Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction

Frontiers in Cardiovascular Medicine, 2021
Aims: This retrospective study assessed the association between sulfonylureas use and infarct size in patients with type 2 diabetes (T2DM) and ST-segment elevation myocardial infarction (STEMI) by myocardial enzymology indexes and cardiac magnetic ...
Fang-Hong Shi, Fang-Hong Shi, Hao Li, Ling-Cong Kong, Long Shen, Yi-Hong Jiang, Zhi-Chun Gu, Heng Ge   +7 more
doaj   +1 more source

Gliclazide MR in the structure of antihyperglycemic therapy according to the data of Moscow region diabetes register

Сахарный диабет, 2022
Background: Sulfonylureas (SU) are often used for second and third line type 2 diabetes mellitus (T2DM) therapy. Currently, there are no unified recommendations governing the choice of drugs for the second line therapy.
I. V. Misnikova, Yu. A. Kovaleva, V. A. Gubkina, A. V. Dreval   +3 more
doaj   +1 more source

Pharmacologically relevant drug interactions of sulfonylurea antidiabetics with common herbs [PDF]

Journal of HerbMed Pharmacology, 2018
Introduction: Sulfonylurea antidiabetics are insulin secretogogues useful in the treatment of type 2 diabetic patients. The probability of adverse drug interactions is high in patients taking sulfonylureas and other drugs including herbal medicines.
Naina Mohamed Pakkir Maideen, Rajkapoor Balasubramaniam   +1 more
doaj   +1 more source